Only 42 elderly patients were included in The National Institute of Neurological Disorders and Stroke (NINDS) intravenous tissue plasminogen activator (ivtPA) trial (16, 17) and they were excluded from the large IVT trials such the European Cooperative Acute Stroke Study (ECASS) III (18) and Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST) (19). This evidence concerns the gene PLAT and stroke disorder.